Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Specialty Generics Market Valuation Change Between Now And 2029?

In recent times, the specialty generics market has seen a swift expansion in its size. The market, which was at $95.87 billion in 2024, is predicted to rise to $107.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.7%. This notable growth in the historical period is primarily due to the expiration of patents for branded drugs, the escalating demand for affordable alternatives, regulatory backing for approving generic drugs, mounting pressures from healthcare costs, alongside the increase in chronic diseases and an aging global population.

The market for specialty generics is projected to experience substantial expansion in the upcoming years, reaching an estimated worth of $185.68 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 14.7%. This predicted growth over the forecast period can be ascribed to several factors such as the development of the biosimilars market, increased focus on specialty generic injectables, the application of 3D printing in specialty generic production, and the market growth of specialty generics in developing economies. The forecast period also suggests significant trends including the personalization and targeting of specialty generics, strategic partnerships, and collaboration in the development of generic drugs. Additionally, there will be a concentrated effort towards creating abuse-deterrent formulations, incorporating digital health technologies within specialty generics, and regulatory initiatives aimed at hastening the approval of complex generics.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7781&type=smp

What Core Drivers Are Expected To Influence The Specialty Generics Market?

The escalating prevalence of chronic ailments is predicted to fuel the specialty generic market’s demand. Such diseases are protracted conditions that typically aren’t entirely curable, but can at times be managed and controlled. The shift in lifestyles, dietary habits, and lack of weight control serve as catalysts for these chronic issues, with some severe chronic diseases even carrying a risk for cancer. The increasing incidence of these ailments necessitates the use of specialty generic drugs to manage complicated chronic disorders. For example, in September 2022, the World Health Organization, a specialist agency from Switzerland affiliated with the United Nations, reported that of the annual global deaths, 74% or 41 million were attributed to non-communicable diseases (NCDs) or chronic diseases. Statistics showed 17.9 million deaths were due to cardiovascular diseases, 9.3 million were cancer-related, 4.1 million were from chronic respiratory diseases, while diabetes accounted for 2.0 million deaths. Consequently, the rise in chronic diseases is propelling the growth of the specialty generic market.

Which Segments Define The Structure Of The Specialty Generics Market?

The specialty generics market covered in this report is segmented –

1) By Route Of Administration: Injectables, Oral, Other Route Of Administration

2) By Indication: Oncology, Autoimmune Diseases, Infectious Diseases, Other Indication

3) By Distribution Channel: Retail Pharmacies, Specialty Pharmacies, Hospital Pharmaciesx

Subsegments:

1) By Injectables: Intravenous (IV) Injectables, Intramuscular (IM) Injectables, Subcutaneous (SC) Injectables

2) By Oral: Tablets, Capsules, Liquid Formulations

3) By Other Route Of Administration: Topical, Transdermal, Inhalation

What Strategic Shifts And Innovations Are Influencing The Specialty Generics Market?

Key players within the specialty generic market, such as Lisdexamfetamine Dimesylate, are gaining authorization approvals, meeting a critical demand for such medications. This approval process is related to specialty generics, referring to regulatory permission given to products that are bioequivalent and therapeutically equivalent to branded specialty drugs which are often utilized for intricate or rare health conditions, following the expiration of their patent protection. For instance, in August 2023, the Ireland-based specialty pharmaceutical firm, Mallinckrodt plc, acquired FDA approval for their Lisdexamfetamine Dimesylate Capsules under the SpecGx LLC Specialty Generics division, designed for treating Attention-Deficit/Hyperactivity Disorder (ADHD). Lisdexamfetamine Dimesylate is a specialty generic and federally controlled substance (CII) for the treatment of ADHD among other conditions.

Who Are The Most Influential Companies In The Specialty Generics Market?

Major companies operating in the specialty generics market include Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC, Mallinckrodt Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Which Region Is Forecasted To Lead The Specialty Generics Market In The Coming Years?

North America was the largest region in the specialty generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specialty generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=7781&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model